Concourse Financial Group Securities, Inc. Clovis Oncology, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share
Q3 2022 Nov 15, 2022	BUY	$1.05 - $2.85 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$0.63 - $2.96 $0 - $0
Q1 2022 May 09, 2022	BUY	$1.43 - $3.14 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$2.7 - $4.76 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$4.06 - $5.8 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$5.02 - $7.05 $0 - $0
Q1 2021 May 13, 2021	BUY	$4.81 - $10.34 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$4.13 - $6.41 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$4.82 - $7.72 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$5.69 - $9.69 $0 - $0
Q1 2020 May 13, 2020	BUY	$3.77 - $11.0 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$3.0 - $16.43 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$3.93 - $15.35 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$12.81 - $25.67 $0 - $0
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $0 - $0
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $0 - $0
Q3 2018 Nov 13, 2018	BUY	$29.37 - $49.48 $0 - $0

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account